{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-053949","form_type":"8-K","ticker":"AGEN","cik":"0001098972","company_name":"AGENUS INC","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.277456+00:00","generated_at":"2026-06-02T16:00:12.606161+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Agenus signs $100M royalty financing with Ligand; $75M upfront for BOT/BAL and partner programs","bullets":["Ligand pays $75M at closing for 18.75% of royalties and 31.875% of milestones on six partnered oncology programs, plus 2.625% royalty on BOT/BAL net sales.","Ligand has option to invest additional $25M on same terms; Agenus may syndicate up to $125M more, bringing total potential to $200M.","Warrant issued to Ligand for 867,052 shares of AGEN common stock at $17.30, exercisable until May 6, 2029.","Funds will support BOT/BAL confirmatory Phase 3 trial in r/r MSS CRC liver metastases-negative and launch readiness activities.","Covered programs include BMS-986442, AGEN2373 (Gilead), INCAGN2385/2390 (Incyte), MK-4830 (Merck), and UGN-301 (UroGen)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-053949","json":"https://secwatch.observer/filing/0000950170-24-053949.json","markdown":"https://secwatch.observer/filing/0000950170-24-053949.md","text":"https://secwatch.observer/filing/0000950170-24-053949.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1098972/000095017024053949/0000950170-24-053949-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1098972/000095017024053949/agen-20240506.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T16:00:12.606161+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d8e3f1a16dd1eb92ef11f08aac136bb3b7ae6286","claim":"AGENUS INC entered into Purchase Agreement with Ligand Pharmaceuticals Incorporated valued at $75 million (effective 2024-05-06).","evidence_excerpt":"On May 6, 2024, Agenus Inc. (the “Company”), Agenus Royalty Fund, LLC and Agenus Holdings 2024, LLC entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Ligand Pharmaceuticals Incorporated (“Ligand”) for the sale to Ligand of the following (the “Purchased Assets”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1098972/000095017024053949/0000950170-24-053949-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Ligand Pharmaceuticals Incorporated"},{"label":"Value","value":"$75 million"},{"label":"Effective","value":"2024-05-06"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}